Accelerated cholesterol and lipid metabolism are the hallmarks of cancer and contribute to malignant transformation due to the obligatory requirement for cholesterol for the function of eukaryotic membranes. To build new membranes and maintain active signaling, cancer cells depend on high intensity of endogenous cholesterol biosynthesis and uptake of lipid particles. This metabolic dependency of cancer cells on cholesterol and other lipids is tightly regulated by the cholesterol homeostasis network, including (i) sterol response element-binding proteins (SREBP), master transcriptional regulators of cholesterol and fatty acid pathway genes; (ii) nuclear sterol receptors (liver X receptors, LXR), which coordinate growth with the availability of cholesterol; and (iii) lipid particle receptors, such as low-density lipid particle (LDL) receptor, providing exogenous sterol and lipids to cancer cells. In addition, activity of oncogenic receptors, such as MUC1 or EGFR, accelerates sterol uptake and biosynthesis. Therefore, a general strategy of reducing the cholesterol pool in cancer cells is challenged by the highly efficient feedback loops compensating for a blockade at a single point in the cholesterol homeostatic network. Besides the well-established structural role of cholesterol in membranes, recent studies have uncovered potent biologic activities of certain cholesterol metabolic precursors and its oxidized derivatives, oxysterols. The former, meiosis-activating sterols, exert effects on trafficking and signaling of oncogenic EGF receptor (EGFR). Cholesterol epoxides, the highly active products of cholesterol oxidation, are being neutralized by the distal sterol pathway enzymes, emopamyl-binding protein (EBP) and dehydrocholesterol-7 reductase (DHCR7). These recently discovered "moonlighting" activities of the cholesterol pathway genes and metabolites expand our understanding of the uniquely conserved roles these sterol molecules play in the regulation of cellular proliferation and in cancer. Clin Cancer Res; 20(1); 28-34. Ó2013 AACR.
Background

Synthesis of cholesterol and its intermediates
Cholesterol is a crucial component of cell membranes and its homeostasis is critical for normal cell functioning (1) . Cholesterol biosynthesis is highly conserved in all the eukaryotes with a minimal difference between the end products, human cholesterol, and fungal ergosterol, arising at the level of zymosterol conversion (2) . A series of elongation reactions of the nonaromatic fatty acid produces farnesyl pyrophosphate, which is converted to squalenethe first four-ring sterol precursor in the pathway (3) . The presqualene steps of the cholesterol pathway produce isoprenoids, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate, which are critical for membrane anchoring of multiple signaling oncogenic proteins such as RAS (4), phosphoinositie 3-kinase (5) , and AKT (6) . Squalene epoxidase and lanosterol synthase catalyze the conversion of squalene to a relatively inert sterol, lanosterol, which is highly abundant in skin appendages such as hair (from lanus, Latin, wool; ref. 3) . The subsequent steps produce a series of precursors possessing various biologic activities. For instance, highly biologically active C4-methylated sterols are also known as meiosis-activating sterols (MAS; 7) for their unique role in regulating the second division of meiosis in the gonads. The final product of the pathway, cholesterol, is subjected to a series of oxidative conversions in the "tail" and the "B" ring of the molecule, to produce bile acids, steroid hormones, and vitamin D (8, 9) . Metabolic arrest of the presqualene steps of the cholesterol pathway during normal development is universally lethal in all eukaryotes due to the disruption of critical membrane-based signaling. Contrastingly, mutations in the distal cholesterol pathway genes are viable but produce severe developmental defects (10) . Therapeutic trials of cholesterol supplementation have led to only modest improvements (11, 12) , thus suggesting unique biologic activities for the accumulating intermediate sterol metabolites specific for each genetic lesion.
Maintenance of high sterol levels in cancer cells
More than a hundred years ago an association between lipid metabolism and tumor progression was first investigated by John Holden Webb, who suggested that cancer was due to crystallization of cholesterol from living cells (13) . Since that time, the involvement of lipid metabolism in tumorigenesis has been thoroughly investigated. Cholesterol composition of cellular membranes has been established as an essential metabolic requirement for cell divisions (14, 15) , and it was shown that proliferating cells increase cholesterol uptake (16, 17) . Cancer cells adapt to maintain high intracellular cholesterol through different mechanisms (Fig. 1) , including accelerated endogenous production of cholesterol and fatty acids (18) (20) , or by increasing the uptake of low-density lipid particles (LDL; ref. 21) . Deregulation of cholesterol homeostasis can be a powerful tool to suppress cancer growth and signaling of oncogenic receptors such as EGF receptor (EGFR) family (16, 22, 23) . Cholesterol promotes cancer signaling, in part, due to the assembly of cholesterol-rich membrane microdomains called lipid rafts ( Fig. 1; ref. 24 ). The overall dependency of rapidly dividing cells on lipid and sterol metabolism makes deregulation of these metabolic pathways a promising anticancer target. In this review, we focus on the recent discoveries in the function of sterol metabolites and cholesterol pathway enzymes in cancer.
The endocytic matrix
As a major component of lipid rafts, cholesterol is the main critical component of lipid rafts activating multiple membrane-bound receptor signaling pathways (ref. 1, 24; Fig. 1 ). Lipid rafts regulate endocytosis and catalytic activities of surface receptors, including signaling duration, receptor recycling, and receptor stability (1) . Any essential biologic process involving nondiffusible protein complexes is dependent on highly coordinated budding and fusion of the cellular membranes, thus forming the so-called "endocytic matrix" within the cell (25) . The function of the EGFR in the context of this "matrix" has been thoroughly investigated. Endocytosis is one of the major mechanisms of attenuation of EGFR (and other receptor tyrosine kinases) signaling, as it permits the removal of the receptor from the cell surface and its delivery to the sites of inactivating endoplasmic Figure 1 . Cholesterol homeostasis regulation. A, activated EGFR and mTOR signaling promotes SREBP-SCAP complex to move to the Golgi, in which it undergoes cleavage to form an active nuclear SREBP fragment (N, blue diamonds). B, in the nucleus, the nuclear fragment of SREBP (N, blue diamond) binds to the sterol regulatory element DNA sequences (56) and induces expression of fatty acid and cholesterol pathway genes and the LDLR. C, uptake of exogenous LDL cholesterol is via its binding to LDLR. LDLR internalization and degradation in lysosomes and autophagosomes releases free cholesterol (34) . Under the conditions of excess, cholesterol acts as a negative regulator by binding to SCAP and blocking SREBP processing.
EGFR
reticulum-based phosphatases (26, 27) . Sigismund and colleagues revealed that EGFR signaling might be regulated by two different ways of internalization (28) . They found that low EGF cell stimulation causes clathrin-mediated endocytosis (CME) predominantly, which promotes mostly recycling of the EGFR to the cell surface, and this, in turn, allows for prolonged CME-dependent signaling. Stimulation with high EGF level activates non-clathrin endocytosis (NCE) that sends a sizeable pool of receptors to degradation, thereby protecting the cell from overstimulation. Detailed kinetic analysis of the EGFR endocytosis and signaling showed marked dependency of NCE on the membrane cholesterol contents (28) .
Participation of cholesterol metabolites in endocytic trafficking of signaling molecules has been discovered in our recent studies (23, 29) : Depletion of the C4-demethylating enzymes [sterol C4-methyl oxidase-like (SC4MOL) and NADP-dependent steroid dehydrogenase-like (NSDHL)] markedly sensitizes cancer cell lines and tumor xenografts to EGFR-targeting drugs via accelerated shuttling of the internalized EGFR endosomes toward late endosomes and lysosomes for degradation. The analysis of the highly evolutionary conserved (30, 31) interactions for these sterol pathway genes demonstrated significant enrichment for multiple components of the vesicular trafficking apparatus in the cell (23) . Furthermore, genetic deficiency of NSDHL in heterozygous bare patches (Bpa 1H/þ ) mice (32) consistently revealed a direct effect on EGFR signaling in keratinocytes. The skin areas expressing the mutant X-linked Bpa 1H allele (NSDHL null areas) showed a marked downregulation of the EGFR signaling coincident with reduced proliferation (23) .
The regulation of receptor endocytosis via cholesterol homeostasis has been shown for multiple receptors, and thus may represent a general mechanism. For example, melanocortin-4 receptor (MC4R) endocytosis to maintain MC4R responsiveness to its agonist a-melanocyte-stimulating is highly sensitive to depletion of membrane cholesterol (33) .
Membrane cholesterol concentration also regulates the extracellular LDL cholesterol uptake via binding with the LDL receptor (LDLR) and its following internalization. The "classical" way of LDLR internalization is based on clathrin-dependent endocytosis. Acidification of early endocytic vesicles liberates LDL from the receptor and allows the cargo to be delivered to lysosomes, in which the lipoprotein particle is degraded and cholesterol is salvaged for cellular use (ref. 34 ; Fig. 1 ). The endocytosis of LDLR is tightly regulated by proprotein convertase subtilisin/kexin type 9, a serine endoproteinase, which binds to the extracellular domain of LDLR and induces its internalization (35) . Endocytosis of LDLR via the clathrin-mediated pathway is accelerated in cells with low intracellular sterol level. The uptake of LDL cholesterol is highly responsive to even small changes of cholesterol concentration in the endoplasmic reticulum membranes because deprivation of cholesterol leads to SREBP cleavage-activating protein (SCAP)-mediated induction of the SREBP transcription factors activation (36) , which in turn regulates LDLR transcription (37) .
Conversely, increased sterol concentrations activate the sterol-sensing nuclear receptors liver X receptors (LXR) a and b (Fig. 2) . Activated LXRs, as heterodimers with retinoid X receptors (RXR), generally reduce intracellular cholesterol through the expression of cholesterol efflux proteins such as ABC transporters ABCA1 and ABCG1, ADP ribosylation factor-like 7, and apolipoprotein E (38) . LXR also reduces uptake of the LDL cholesterol via the transcription of an E3 ubiquitin ligase, inducible degrader of LDLR (IDOL; ref. 39) . IDOL promotes internalization and degradation of LDLR in a clathrin-independent manner (34). An LXRabinding site in the proximal promoter region of the rat 7a-hydroxylase CYP7A also promotes the removal of cholesterol by increasing its conversion to bile acids (40) . Under physiologic conditions, oxysterols such as 22(R)-hydroxycholesterol, 24(S),25-epoxycholesterol, and 24(S)-hydroxycholesterol, strongly induce LXRa and LXRb transcriptional targets (40), but not in response to other sterols (lanosterol, desmosterol, steroid hormone precursors, testosterone, progesterone, or bile acids; ref. 41 ).
"Moonlighting" functions of cholesterol pathway
Although cholesterol composition of the cellular membranes has been the focus of research, recent data highlight the unique biologic properties of the sterol pathway metabolites. Among the signaling pathways that are critically dependent on the intact cholesterol biosynthesis, sonic hedgehog is arguably the best studied (42) . Oncoprotein Another example of sterol pathway metabolite involvement in cancer is MAS. MAS are the cholesterol pathway intermediaries downstream of lanosterol, and they play a unique physiologic role to activate meiotic resumption in mouse oocytes in vitro (7). FF-MAS (4,4-dimethyl-5a-cholesta-8, 14, 24-triene-3b-ol) was extracted from human preovulatory follicular fluid and T-MAS (4,4-dimethyl-5a-cholest-8,24-diene-3b-ol) from the bull testicular tissue (44) . In addition, MAS have been identified as natural ligands for LXRs a and b (41). We have recently reported that sterol SC4MOL and NSDHL, catalyzing oxidative demethylation of the MAS cholesterol precursors at C4 position, also regulate the endocytic traffic of EGFR in normal and cancer cells (23) .
One step below SC4MOL and NSDHL, emopamyl-binding protein (EBP) in a complex with dehydrocholesterol-7 reductase (DHCR7) catalyzes isomerization of the doublebond between C7 and C8 in the second cholesterol ring (45) . Besides binding of different structural classes of ligands such as ring B oxysterols, there seems to be a new "moonlighting" function for this protein complex. As it turns out, this complex also mediates a previously enigmatic activity of cholesterol epoxide hydrolase (ChEH; 46). Furthermore, the biologic activities of the cholesterol epoxides regulated by EBP/DHCR7 extend far beyond the canonical cholesterol. A naturally occurring steroidal alkaloid, 5a-hydroxy-6b-[2-(1H-imidazol-4-yl)ethylamino]cholestan3b-ol, otherwise known as dendrogenin A, is produced in normal, but not in cancer cells, via an enzymatic conjugation of 5,6a-epoxy-cholesterol and histamine (47, 48) . This sterol conjugate has been shown to suppress cancer cell growth and to induce differentiation in vitro in various tumor cell lines of different types of cancers (48) . It also inhibited tumor growth in melanoma xenograft studies in vivo and prolonged animal survival: 40% survivors at day 50 compared with none in the control (47) . The activity of another sterol synthesizing enzyme, DHCR24, has been implicated in regulation of KRAS-induced senescence via deregulation of P53 (49, 50) .
Clinical-Translational Advances
Opportunities for targeting cholesterol homeostasis in cancer
Dependency of cholesterol offers a range of therapeutic opportunities to target cholesterol homeostasis in cancer. SREBPs and LXR are considered as potent targets because coordinated activities of these proteins control cellular proliferation (51) . Effective and orally bioavailable synthetic LXR agonists such as GW3965 may offer an opportunity to antagonize the G 1 -to-S cell-cycle progression in cancer cells via the active form of retinoblastoma and deregulation of cyclin-dependent kinases as well as induction of the negative regulator p15 (52) . The antiproliferative effect of the LXR agonist T0901317 was demonstrated to suppress b-catenin transcriptional activity by direct interaction in the colon cancer HCT116 cell line in vitro (53) . Activation of LXR in vivo in the azoxymethane/dextran and Apc À/þ animal models of colon cancer resulted in blocking cells at the MAS influences endocytosis of surface receptors (e.g., EGFR) by promoting shuttling of the internalized EGFR to late endosomes for degradation that may be important for EGFR targeting in cancer and developmental defects in the hereditary cholesterol pathway gene deficiencies (23) . B, some endogenously generated oxysterols (e.g., 22-R-hydroxycholesterol, 25-hydroxycholesterol) bind to LXR/RXR heterodimeric nuclear receptors. LXR induces expression of ABCA1 and ABCG1 efflux pumps, and cholesterol conversion to bile acids via CYP7A1 (40, 62) . LXR also promotes LDLR degradation via increased endocytosis and ubiquitin ligation by IDOL E3 ligase (50) . C, a complex of EBP and DHCR7 known as ChEH disposes of toxic cholesterol epoxides and promotes growth of tumors cells. Contrastingly, in normal tissues, cholesterol epoxides react with histamine to produce dendrogenin A, which promotes cell differentiation and suppresses cell growth (18, 26, 27) .
G 1 phase of the cell cycle and activating an apoptosis program that led to the 70% reduction in tumor number and the approximately 40% reduction in tumor size (54) . Another possibility to target cholesterol homeostasis is based on the ability of cancer cells to develop mechanisms to accumulate cholesterol. For example, prostate cancer cells showed high expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), but failed to express the major cholesterol exporter ABCA1 (55) . Statins block the de novo synthesis of cholesterol at its rate-limiting step (16, 56) . The efficacy of this approach, however, is limited by toxicities arising from the impairment of mitochondrial metabolism and of small GTPases (e.g., Rho and Ras) dependent on isoprenoids for membrane anchoring (56) . Moreover, cancer cells can bypass the effects of statins by unrestrained cholesterol importation via the LDLR pathway (16) and increased expression of the pathway genes via the SREBPs (57) .
To overcome such redundancy of cholesterol regulation, blocking multiple compensatory targets may potentially yield synthetic lethal interactions (29) . In cancer cells, cholesterol uptake and endogenous production are stimulated by the oncogenic signaling. For example, glioblastoma multiforme, an aggressive form of brain tumor, a constitutively active mutated EGFR-variant III promotes LDLR expression and tumor growth (16) . Such a dependency relationship between the EGFR pathway and the lipid biosynthesis is regulated via transcriptional activity of SREBP1 (16) .
Another mTOR-dependent mechanism of lipid biosynthesis activation has been discovered recently involving lipin-1, a conserved negative regulator of nuclear translocation of SREBP1 (58) . Lipin-1 is highly homologous to the Caenorhabditis elegans LPIN-1 and has been shown to regulate nuclear envelope and nuclear shape (58) . Torin-1, an mTOR kinase inhibitor, has been effective in preventing lipin-1 phosphorylation by mTOR and SREBP1 nuclear translocation. Thus, mTOR kinase inhibitors may be effective in suppressing mTOR pathwayinduced sterol and lipid biosynthesis in cancer. Finally, direct inhibitors of SREBP have been developed. One such compound, betulin, a natural pentacyclic triterpene, specifically inhibits SREBP proteolysis by facilitating the interaction of the SCAP and a negative SREBP regulator, INSIG (insulin-induced gene 1). As a result, the cholesterol biosynthesis is inactivated both in vitro and in vivo (59).
Conclusions
In summary, the high dependency of cancer cells on accelerated biogenesis and uptake of lipids and cholesterol lends itself as a therapeutic opportunity for metabolic targeting of cancer growth. Most previous attempts to target cholesterol metabolism in cancer have used HMGCR inhibitors, statins, or farnesyl transferase inhibitors acting at the level of nonaromatic steps of the cholesterol pathway. Multiple redundancies and feedback mechanisms highly abundant in the mammalian metabolic systems (60), often preclude successful pathway targeting at a single gene level. Instead, combinations of signaling inhibitors of the EGFR and/or mTOR pathways with a growing number of inhibitors of various regulatory molecules in the cholesterol homeostasis may prove to be the winning anticancer strategy. Emerging data on unprecedented biologic activities of certain sterol metabolites (23, 47) and opportunities to activate LXRs (16) or direct inhibition of SREBPs (59, 61) may be fruitful strategies to win over cancer by cholesterol starvation.
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